(Reuters) -Eli Lilly hit $1 trillion in market value ​on Friday, making it the first ‌drugmaker to enter the exclusive club dominated by tech ‌giants and underscoring its rise as a weight-loss powerhouse.

Here are some reactions to Lilly joining the trillion dollar club: ⁠

EVAN SEIGERMAN, ‌ANALYST AT BMO CAPITAL MARKETS

"The current valuation points to investor confidence ‍in the longer-term durability of the company's metabolic health franchise. It also suggests that ​investors prefer Lilly over Novo in ‌the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."

HANK SMITH,⁠ DIRECTOR &​ HEAD OF INVESTMENT STRATEGY ​AT LILLY SHAREHOLDER HAVERFORD TRUST

"Investors have historically liked secure earnings growth ‍and (⁠Eli Lilly) is the only large cap pharma that has that kind of ⁠earnings profile."

(Reporting by Siddhi Mahatole ‌and Shashwat Chauhan in Bengaluru; ‌Editing by Leroy Leo)